Peptides AcademyGLP-1 Analog Peptides
Semaglutide, liraglutide, and related incretin-based peptides approved for glycemic control and chronic weight management.
GLP-1 Receptor Agonists (2)
Liraglutide
Saxenda / Victoza
The first GLP-1 receptor agonist approved for chronic weight management (Saxenda, 2014) — an acylated human GLP-1 analog with ~13-hour half-life dosed once daily.
0.6–3 mg daily (escalating)FDA-approved (Victoza, Saxenda)
Semaglutide
Ozempic / Wegovy / Rybelsus
Long-acting GLP-1 receptor agonist — FDA-approved for type-2 diabetes and chronic weight management, landmark for its ~15% mean weight reduction in STEP trials.
Ozempic: 0.25–2 mg weekly; Wegovy: up to 2.4 mg weeklyFDA-approved (Ozempic, Wegovy, Rybelsus)